Content Type: Article

  • Key Takeaways | IRS & FTB: Ultra High-Net-Worth Targets, Taxes & Tips

    Key Takeaways | IRS & FTB: Ultra High-Net-Worth Targets, Taxes & Tips

    ARTICLE

    Key Takeaways | IRS & FTB: Ultra High-Net-Worth Targets, Taxes & Tips

    October 29, 2024

    Read time: 3 min

    Key takeaways
    Overview

    This session of the Private Client West Coast Forum 2024 explored the current state of audits and tax controversy and shared practical advice to prepare for challenges ahead of a contest with the IRS or Franchise Tax Board (FTB).

    Session panelists included Charles J. Moll, III and Kevin Spencer.

    In depth

    Key takeaways included:

    • With increased funding under the Inflation Reduction Act of 2022, the IRS intends to spend billions of dollars on improving its technology and hire 87,000 new employees over the next 10 years. Taxpayers can expect more in-depth audits of high-net-worth individuals and their related returns where the taxpayer has a controlling interest and where “a significant compliance risk” is deemed to exist. It’s important to note that the IRS’s plans may face significant changes under the Trump administration, potentially reducing the scope and focus of these enforcement efforts.
    • When a taxpayer is unable to reach an agreement with the IRS during an audit, the taxpayer can consider Fast Track mediation, an alternative dispute resolution option before proceeding to IRS appeals.
    • In anticipation of potential audits, taxpayers can prepare now to address their tax position by ensuring sufficient tax deposits are made, identifying potential tax risks, and preparing and gathering necessary documentation to substantiate their tax positions. These and other preparation steps can be completed with the help and advice of legal counsel.
    • Among state and local tax developments, taxpayers with potential tax obligations in two or more states may be aware of tax credits available for taxes paid to their non-resident state, which can be used as an offset against their resident state income tax. These taxpayers may also want to consider similar local jurisdiction tax credits and their availability in the case of Zilka v. City of Philadelphia (Tax Review Board, No. 23-914), which is currently pending before the US Supreme Court.
    Authors

    Charles Moll III

    Partner

    San Francisco

    More insights

  • Key Takeaways | Family Offices: Evolution & Efficiencies

    Key Takeaways | Family Offices: Evolution & Efficiencies

    ARTICLE

    Key Takeaways | Family Offices: Evolution & Efficiencies

    October 29, 2024

    Read time: 2 min

    Key takeaways
    Overview

    This session of the Private Client West Coast Forum 2024 focused on recent developments, including income tax planning to support investment performance, executive compensation planning, private placement life insurance (PPLI), exchange-traded fund structures, and profits interests.

    Session panelists included Katy Crafton Fluet and Patrick J. McCurry.

    In depth

    Key takeaways included:

    • The Internal Revenue Service (IRS) recently announced the selection of Jeffrey Erickson as Associate Chief Counsel to lead the newly created Passthroughs, Trusts and Estates office. The office will focus exclusively on partnerships, S corporations, trusts, and estates. This decision indicates the IRS’s heightened focus on wealth transfer and related tax planning.
    • Lender planning is likely to remain relevant even after the sunset of the Tax Cuts and Jobs Act repeal of the Section 212 deduction, due to the 2% floor and the potential application of the alternative minimum tax.
    • Tax-loss harvesting using long and short positions has significantly increased in popularity. However, caution is warranted regarding several income tax issues, including the economic substance doctrine, fee deductibility, and passive activity losses.
    • PPLI can be an effective planning solution in the right circumstances. However, costs, complexity, and investor control are important planning considerations.
    • Executive compensation planning has become a common practice to attract and retain talent in family office spaces. Planning considerations should include tax, valuation, and other contractual implications when employees exit the structure.
    Authors

    Katrina Crafton Fluet

    Partner

    Silicon Valley, San Francisco

    Patrick J. McCurry

    Partner

    Chicago

    More insights

  • Bulletin Concurrence XII

    Bulletin Concurrence XII

    ARTICLE

    Bulletin Concurrence XII

    October 2024

    Read time: 2 min

    Key takeaways
    Overview

    We are delighted to share the twelfth Bulletin Concurrence which aims to keep you up to date with the key developments in competition law over the second quarter of 2024and beyond.

    Read the full Bulletin (in French) here.

    In depth
    Authors
    More insights

  • Growing Interest in Utilising Equity Commitment Letters in the Context of Sponsor Margin Loans

    Growing Interest in Utilising Equity Commitment Letters in the Context of Sponsor Margin Loans

    ARTICLE / CLIENT ALERT

    Growing Interest in Utilising Equity Commitment Letters in the Context of Sponsor Margin Loans

    28 October, 2024

    Read time: 7 min

    Key takeaways
    Overview

    Equity Commitment Letters (ECL) are legal documents pursuant to which one party (typically the main fund or multiple funds managed by the sponsor) (the ECL Provider) commits to providing a certain amount of capital, usually cash, to another party (typically the borrower or borrowers owning the shares that back an underlying loan agreement) (the ECL Receiver) if certain triggers occur.

    • Over the past few months, we have observed a growing interest in utilization of ECLs from both lenders and borrowers.
    • This interest stems from the additional credit support ECLs provide to borrowers for the benefit of lenders, while addressing various structural issues such as tax and regulatory concerns.
    • ECLs are becoming an essential tool in the financial landscape, particularly in the context of sponsor-backed Margin Loans (MLAs), where they act as a safeguard to ensure the fulfillment of loan obligations.

    This client alert aims to provide a comprehensive overview of ECLs, their key provisions, and their significance in MLA transactions. By understanding the intricacies of ECLs, stakeholders can better navigate the complexities of these financial instruments and leverage their benefits effectively.

    In depth

    Reasons for ECLs

    • In the context of MLAs facing single-purpose borrowers, the ECL acts as a safeguard to ensure that if there were a shortfall in funding, especially in case of a margin call, a capital injection by the ECL Provider will be made to ensure the ECL Receiver’s underlying loan obligations are satisfied.
    • With a large fund standing behind the ECL, lenders typically feel more comfortable to relax the otherwise very tight timelines within which any cash has to be posted upon margin call, or to relax the triggers that result in mandatory prepayments.
    • The use of ECLs may also be driven by tax reasons whereby the ECL Provider may prefer not to be facing a lender directly, in order to avoid negative tax consequences for itself and/or any of its investors.
    • To the extent the underlying fund is subject to any borrowing or analogous limits, ECLs may be a helpful tool to ensure that no breach of those limits will occur, while being able to provide credit support to the ECL Receiver.

    Obligations of the ECL Provider

    The ECL Provider is obligated to inject the capital as stated in the ECL. Where multiple funds provide the ECL, their obligation is typically joint and several and any of the funds can fully fund the obligations under the ECL as selected by the sponsor. The ECL does not create any direct, contractual obligations on the LPs invested in the main fund.

    Key Provisions of the ECL

    Amount of Capital

    The ECL specifies the maximum amount of capital (i.e. the commitment) that the investors commit to providing.

    • In an MLA transaction, the ECL commitment generally matches the underlying loan obligations.
    • In a subscription finance transaction, the commitment tends to equate to the ECL Provider’s unfunded capital commitments.

    The payment is typically due to the borrower (not to the lender(s)), but can be structured in the ECL as being made directly to a secured collateral account, on behalf of the borrower, to satisfy the obligations under the MLA. Where the borrower is set up as a bankruptcy remote single-purpose vehicle, there is limited risk that other creditors would be able to establish a claim in an attempt to benefit from the funds provided by the sponsor pursuant to the ECL.

    Conditions for Capital Injection

    The ECL sets out specific conditions under which the capital must be injected. This could include:

    • A margin call on the MLA due to a fall in the collateral value; or
    • A need for additional funds to maintain the required LTV.

    Timelines

    The ECL outlines the timeframe within which the ECL Provider must provide the capital after the specified condition occurs. This varies in the market between a few days (e.g. the second business bay) and several weeks (e.g. 12 business days).

    ECLs are either provided upfront (at the signing of the MLA), ‘in exchange’ for more relaxed terms around triggers; or a form of ECL is appended to the MLA and is to be delivered upon a specific trigger as a way for the ECL Provider to delay any enforcement procedures, thereby getting additional time to obtain the funds to provide additional capital to the ECL Receiver. In these situations, the ECL Provider typically confirms that it has called for capital at the same time as providing an executed ECL to the ECL Receiver and this allows the ECL Receiver to benefit from extended cure period under the MLA terms.

    Third-Party Rights

    Unlike guaranty agreements, lenders and administrative agents under a syndicated MLA are not parties to the ECL but can nevertheless enforce the terms of the ECL through the administrative agent (or directly by the lender in the context of non-syndicated MLAs), relying on third-party rights provisions set out in the ECL.

    A third-party clause in the ECL ensures that no other unsecured creditor of the ECL Receiver should be in a position to enforce the rights under the ECL.

    Representations and Warranties

    Thorough due diligence should drive a tailored set of representations and warranties set out in the ECL or directly in the MLA. In particular:

    • The ECL Provider needs to be permitted under its organizational documents to call capital from its investors in an aggregate amount at least equal to the aggregate commitments under the ECL from the uncalled capital of the ECL Provider.
    • Representations and warranties should prospectively bind the ECL Provider to maintain sufficient headroom in the uncalled capital (taking into account any other guarantees or ECLs granted at any point in the future) that will at all times allow the fund to satisfy its obligations under the ECL.

    It is common to obtain representations and occasionally even warranties from the ECL Provider (under the terms of the ECL) to maintain certain minimum NAV and liquidity, in each case, for the duration of the MLA financing. Additional reporting requirements are often imposed on the ECL Receiver to ensure that the lender can monitor the ECL Provider’s compliance with any such representations and warranties.

    Conclusions

    ECLs offer several attractive features that can significantly enhance the ability of sponsors to raise capital from lenders. They provide a robust mechanism for ensuring that loan obligations are met, thereby offering comfort to lenders and flexibility to borrowers. However, it is crucial to carefully negotiate the terms of ECLs to address potential risks, particularly those related to enforcement.

    Lenders should seek expert legal advice to ensure that all aspects of the ECL are thoroughly vetted, their interests are adequately protected and thorough due diligence is done in order to tailor the representations and warranties set out in the ECL.

    As the use of ECLs continues to grow, understanding their role in MLA transactions, as well as their implications, will be vital for all parties involved. By doing so, lenders and borrowers can leverage ECLs to enhance their financial strategies and achieve their objectives.

    Authors

    Vlad Maly

    Partner

    London – 22 Bishopsgate

    Aymen Mahmoud

    Partner

    London – 22 Bishopsgate

    Giacomo Bertolissi

    Counsel

    London – 22 Bishopsgate

    More insights

  • Decoding the Final HSR Changes: What Investment Funds Should Know

    Decoding the Final HSR Changes: What Investment Funds Should Know

    ARTICLE / CLIENT ALERT

    Decoding the Final HSR Changes: What Investment Funds Should Know

    October 28, 2024

    Read time: 16 min

    Key takeaways
    Overview

    Nature of Transaction Determines Level of Increased HSR Filing Burden  

    On Oct. 10, 2024, the Federal Trade Commission (“FTC” or the “Commission”) — with the concurrence of the Antitrust Division of the US Department of Justice (“DOJ”) — announced the FTC’s unanimous, bipartisan vote to adopt a final rule implementing the most significant changes to the Hart-Scott-Rodino Act (“HSR”) premerger notification rules in the HSR program’s 45-year history (the “Final Rule”). Although nowhere near as sweeping and burdensome as the original proposed changes (on which we wrote in 2023), the changes will meaningfully increase the time and effort required to prepare HSR filings for all reportable transactions.   

    For investment funds (and any other filers), the magnitude of the increased burden will vary with the potential antitrust risks raised by the transaction type.

    The lowest tier of risk, with the corresponding lowest HSR information requirements, is for “select 801.30 transactions,” in which a fund is acquiring securities from a third party or on the open market and will not gain control or board rights. Passive investors acquiring more than 10 percent of an issuer, as well as most investors who engage, or seek to engage, with management would fall into this category. The next tier of antitrust risk, for transactions in which the parties do not have operations in the same industry or any business relationship, has more HSR disclosure requirements. This category includes a private equity firm’s acquisition of a portfolio company in an industry in which the firm currently has no presence. Activist investors seeking board rights, which typically do not have controlling stakes in operating companies or do not focus on a particular industry, also may fall into this middle tier. The highest tier of risk, with the most burdensome HSR information requirements, is for transactions in which the parties operate in the same industry or have a business relationship, such as a private equity firm buying a company as part of a “roll-up” strategy. Within each category of transactions, more information is required from buy-side filers than from the sell-side.

    The FTC notes that the time required to prepare an HSR filing will vary significantly based on the type of filing, “with filings that are more likely to raise antitrust risk requiring higher hours.” The Commission estimates (and many practitioners believe it substantially underestimates) that the average number of additional hours required to prepare an HSR filing under the final rule is 68 hours, with an average low of 10 additional hours for select 801.30 transaction filings by the acquired person and an average high of 121 additional hours for filings from the acquiring person in a transaction with overlaps or supply relationships.

    Unless challenged, the final rule is expected to become effective in the first quarter of 2025, 90 days after its publication in the Federal Register. At that time, the FTC also will lift its “temporary” suspension (since February 2021) of the granting of early termination of the HSR waiting period for transactions that do not raise significant antitrust concerns.

    Select 801.30 Transactions

    Under the HSR Rules, 801.30 transactions are non-negotiated transactions, such as tender offers and acquisitions on the open market or from third parties. Recognizing the low risk that these transactions pose antitrust issues, the Final Rule introduces a new category of “select 801.30 transactions” for which fewer information requirements are imposed. These transactions also should benefit from the reinstatement of early termination.

    A select 801.30 transaction is one in which (1) the acquisition would not confer control, (2) there is no agreement (or contemplated agreement) between the buyer and seller and (3) the acquiring person does not have and will not obtain any right to serve as, appoint, veto, or approve board members, or members of any similar body, of any entity within the acquired person or the general partner or management company of any entity within the acquired person. For example, the acquisition of a non-controlling minority stake of more than 10 percent on the open market by a passive investor with no other ties to the issuer is a select 801.30 transaction. In addition, minority acquisitions by investors engaging or seeking to engage with management, such that they could not rely on the investment-only exemption, would fall into this tier (although investments by activists seeking board rights may be excluded depending on the specifics of the transaction). Executive compensation transactions also qualify as select 801.30 transactions.

    The new HSR form will require substantial additional disclosures from investors making an HSR filing for select 801.30 transactions, but they are significantly less burdensome than the information that will be required for other types of transactions. The new and revised information requirements for select 801.30 transactions include:

    • Description of the fund’s business
    • Description of the fund’s ownership structure
    • Organizational chart (if one exists)
    • Identification of additional minority holders in the organizational chain

    The current form requires disclosure of the holders of 5 percent or more in the ultimate parent entity (“UPE”) and the acquiring entity. Minority holders of intermediate entities in the investment chain do not have to be disclosed and only the general partner must be disclosed for limited partnerships.

    The new form requires disclosure of minority holders (including any trade names under which the holders do business) of 5 percent or more in the acquiring entity, any entity controlling or controlled by the acquiring entity, and any entity that will be created and controlled by the acquiring person to effectuate the transaction (each a “Covered Entity”). If the Covered Entity is a limited partnership, the filer must provide the required information for: (1) its general partner, regardless of the percentage held, and (2) limited partners that (i) hold or will hold 5 percent or more of the partnership, and (ii) have or will have management rights with regard to any Covered Entity or the general partner or management company of any Covered Entity. Management rights are defined as the right to serve as, nominate, appoint, veto or approve board members or individuals with similar responsibilities. Passive limited partners with no management rights do not need to be disclosed.

    The Final Rule contains the following diagram illustrating the disclosure requirements for limited partners. (Under the current rules, only the general partner of the UPE would need to be disclosed.)

    • Identification of certain officers and directors (responses to this item will assist the agencies in identifying director interlocks that may violate Section 8 of the Clayton Act)

    The fund must list all of the officers and directors (or individuals exercising similar functions) of any Covered Entity, as well as those who are likely to serve in one of these positions, who also serve as the officer or director of another entity that operates in the same business or industry as the target, and identify those entities.

    For entities within the acquiring person responsible for the development, marketing, or sale of overlapping products or services, identify the current officers or directors (or individuals exercising similar functions) and those who have served in one of these positions within the three months before filing that also serve as an officer or director of another entity that operates in the same business or industry as the target.

    • Expansion of Competition Documents

    The scope of “Competition Documents,” formerly known as Item 4(c) and 4(d) documents, has been expanded beyond documents prepared by or for officers or directors to now include documents prepared by or for the “supervisory deal team lead,” defined as the individual primarily responsible for supervising the strategic assessment of the deal who is not an officer or director. (If the individuals supervising the strategic assessment of the deal are already either an officer or director, filers may state that this is the case on the form.)

    Filers also should submit any draft Competition Documents that were shared with any member of the board of directors (or similar body). For noncorporate investment funds, this requirement may result in a large number of documents if a member of the deal team also is a member of the “similar body.”

    • Translations for foreign-language documents
    • Whether the fund has (or within one year of filing, had) certain types of agreements with the target, including any agreements with non-compete or non-solicitation terms, licensing agreements, and supply agreements
    • Jurisdictions in which a non-US antitrust or competition authority has been or will be notified of the transaction
    • Subsidies received within the last two years from “foreign entities or governments of concern,” as defined by 42 U.S.C. 18741(a)(5)(C), which currently includes China, Iran, North Korea, and Russia

    Transactions with no overlaps or supply relationships

    The next step up from select 801.30 transactions in terms of new and revised information requirements is for transactions in which the parties do not have any overlaps or supply relationships. This includes acquisitions by agreement between the parties (e.g., a private equity firm acquiring a company that does not compete with or have any supply relationships with the firm’s other portfolio companies), as well as certain acquisitions by activists seeking board rights.

    An investment fund on the buy-side of a transaction with no overlaps or supply relationships must provide all of the information required for select 801.30 transactions listed above, as well as:

    • Organization of controlled entities in investment structure by operating company or operating business (“top-level entity”), including all trade names under which the entities do business
    • Brief description of transaction rationale(s)

    The description must identify each document included with the filing that supports the rationale(s). If documents provide inconsistent rationales, filers should address those inconsistencies.

    • Full transaction agreements, including exhibits, schedules and side letters (but excluding “clean team” agreements)
    • Transaction diagram (if one exists)
    • Overlap description (global, not limited to the US)

    The filer must describe each of its principal categories of products and services (as they generally are described in its ordinary course business documents).

    Transactions involving overlaps or supply relationships

    The last category, for transactions involving overlaps or supply relationships, presents more potential antitrust risks than the first two (select 801.30 transactions and transactions with no overlap or supply relationships) and so is saddled with the most onerous burden in terms of new and revised HSR information requirements. If these transactions are subjected to an in-depth investigation, the Final Rule notes that “the additional information contained in the HSR filing will allow the Agencies to focus their investigation on those aspects of the transaction that create antitrust risk, and minimize ‘overly broad’ Second Requests [that can] impose unnecessary costs and delays.” A private equity firm’s acquisition of a company as part of its roll-up strategy would fall into this category of transactions.

    In addition to all of the information requirements listed in the above two sections, funds filing on the buy-side of a transaction involving overlaps or supply relationships between the parties must provide:

    • Overlap description (global, not limited to the US)

    The filer must describe each of its principal categories of products and services (as they generally are described in its ordinary course business documents).

    In addition, the filer must list and briefly describe each of its current or known planned products or services that competes with (or could compete with) a current or known planned product or service of the target. Known planned products or services may be limited to those referenced in any document submitted with the filing and should reflect only the filer’s knowledge of the other party’s business (i.e., the parties should not exchange information for the purpose of answering this item).

    For each listed product or service currently being sold, the filer must: (1) provide sales for the most recent year (or provide metrics to measure performance if not by revenue); (2) describe the categories of customers that use that product or service; (3) provide the top 10 customers in the most recent year by total sales and (4) provide the top 10 customers for each customer category identified.

    For each listed product or service that is not yet generating revenue, the filer must: (1) provide projected revenue, estimated unit sales, estimated service use, or any metric to measure performance; (2) provide the date that product or service development began; (3) describe the current stage of development; (4) the date that development was or will be completed, including testing and regulatory approvals and (5) the date that the product or service is expected to be sold or otherwise commercially launched.  

    • Supply relationships description (global, not limited to the US)

    The filer must list and describe each product, service or asset (including data) representing at least $10 million in sales in the most recent year that are (1) sold to or purchased from the other party, or (2) sold to or purchased from a business that competes with the other party or that uses the product or service as an input to compete with the other party. The response should reflect only the filer’s knowledge (i.e., the parties should not exchange information for the purpose of answering this item).

    For each listed product, service or asset, the filer also must provide sales data for the most recent year and the top 10 customers (for sales) or suppliers (for purchases).

    • Regularly prepared strategic documents (“Plans and Reports”) provided to CEOs and all Plans and Reports provided to Boards of Directors within a year of filing that discuss market shares, competition, competitors, or markets for any overlapping product or service
    • Pending or awarded defense or intelligence procurement contracts generating more than $100 million of revenue that relate to an overlap between the parties

    Other notable changes

    • Separate forms. Acquiring persons and acquired persons will file using different forms. The HSR form for the sell-side is shorter and requires less information than the form for the buy-side.
    • Letter of Intent. Parties may still file on the basis of a non-definitive agreement, such as an LOI, but the dated document must include “some combination of the following terms: the identity of the parties; the structure of the transaction; the scope of what is being acquired; calculation of the purchase price; an estimated closing timeline; employee retention policies, including with respect to key personnel; post-closing governance; and transaction expenses or other material terms.” The filer also must attest in the HSR filing certification that the document includes sufficient detail about the transaction’s scope.
    • Rollover investors. Minority investors of 5 percent or more in the acquired entity must be disclosed if their investments will “roll over” post-consummation.
    • Minority holdings. Parties must list only minority investments held in entities that are in an overlapping business (i.e., filers no longer have the option to list all minority-held entities).
    • Prior acquisitions by acquired entity. Like the acquirer, the target now must disclose its prior acquisitions in the last five years of entities with revenues in overlapping products or services. (This requirement is aimed at helping the agencies identify strategic “roll-up” transactions.)
    • Geographic market information. The Final Rule updates the lists of industry codes requiring street-level information versus state-level information for the parties’ operations (including franchisees’ operations) in overlapping areas of business.
    • Online portal. The FTC created an online portalfor the public and other interested parties to submit comments related to transactions under review.

    (It could have been worse!)

    Although HSR filings under the final rule will require significantly more time to prepare, the new and revised information requirements are quite curtailed compared to the full body of information and documents envisioned in the original proposed changes. Some of the more burdensome—and controversial—proposals that were dropped include:

    • Disclosure of all minority limited partner investors holding 5 percent or more, including those without management rights
    • Detailed board observer information
    • Requiring drafts of all transaction-related documents, including confidential information memoranda and other deal documents evaluating competition
    • Expanding the disclosure requirement for prior acquisitions to include all entities in the last 10 years with no minimum size requirement, which would have been particularly onerous for firms engaged in serial or “roll-up” transactions
    • Narrative explanation of the deal timeline
    • Creation of organizational charts that included the authors of documents submitted with the HSR filing
    • Information about interest holders that might have material influence on the acquiring person’s management or operations (e.g., creditors, investors with board rights)
    • Detailed disclosures about labor markets and employees
    • Geolocation data for locations of certain overlapping products and services
    • Information about steps taken to preserve documents and use of messaging systems
    • Providing “formerly known as” (“f/k/a”) information for relevant entities

    Key Takeaways

    • Final changes are extensive and will apply to all HSR filers. The changes to the HSR framework affect filers in all reportable deals, with the lightest burden on simple transactions (e.g., open market purchases) and the greatest lift borne by parties to transactions involving overlapping products or services or supply relationships (e.g., serial or “roll up” acquisitions).
    • Suspension on early termination lifted. The FTC will begin granting early termination once the final rule becomes effective. Given that the additional required information will provide the FTC and DOJ with more insight into the proposed transaction earlier in the process, the agencies expect to be able to complete their review of transactions raising little to no antitrust risk more efficiently.
    • Extensive additional lead time required for HSR preparation. In terms of average hours required to prepare HSR filings, the FTC has estimated (and likely significantly underestimated) a minimum average of additional 10 hours for the most simple HSR filings up to 121 hours for acquirers transactions involving overlaps or supply relationships. Buyout firms will need to build sufficient time into their deal timetable to prepare HSR filings and should consider extending purchase agreement commitments to submit filings beyond the customary 5 to 10 business days (perhaps to “as promptly as practicable,” at least for the first HSR filing to be submitted by a particular filer).   
    • Consider filing before the final rule becomes effective in January 2025. If parties are planning to sign the transaction in the near term, they should consider accelerating the HSR timetable to file under the current rules, including whether it may be appropriate to make an HSR filing based on a letter of intent or term sheet.
    • Mitigation of risks needed for document creation. Parties will need to be mindful about wording and perceptions when preparing documents, including ordinary course documents discussing competition sent to the CEO and board of directors that may be prepared months before an HSR filing will be submitted. Care should be taken to avoid, for example, defining a “market” (as it may limit or be inconsistent with how a market may be defined in a competitive analysis), overstating a party’s competitive significance, or using “buzz words” that tend to interest antitrust regulators (e.g., “dominate,” “control,” “leverage,” etc.).
    • Set up a framework to gather and maintain HSR information. Parties can begin collecting and maintaining information that must be provided in HSR filings (e.g., information relating to fund structure, minority investors, third-party positions held by officers and directors, etc.).

    Authored by Peter Jonathan Halasz and Ngoc Pham Hulbig.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.

    In depth
    Authors

    Peter Jonathan Halasz

    Of Counsel

    New York – 919 Third Avenue

    More insights

  • Navigating the buzz: How state agencies are addressing confusion around hemp and low-dose THC beverages

    Navigating the buzz: How state agencies are addressing confusion around hemp and low-dose THC beverages

    ARTICLE

    Navigating the buzz: How state agencies are addressing confusion around hemp and low-dose THC beverages

    Oct 25, 2024

    Read time: 6 min

    Key takeaways
    Overview

    Hemp and low-dose delta-9 tetrahydrocannabinol (THC) beverages continue to flood the marketplace. Depending on the state, these products can be purchased in liquor stores, gas stations, grocery stores, bars, restaurants, and/or online. Despite their rise in popularity and presumed legality under the 2018 Farm Bill, some state agencies have recently made headlines with decisions to ban these products from being sold by alcohol-licensees in their states.

    In this blog post, we walk through some recent examples of how different state alcohol agencies are handling the regulation of hemp and low-dose THC beverages.

    Understanding Hemp and Low-Dose THC Beverages

    As we mentioned in our previous blog post on this topic, hemp and low-dose THC beverages are nonalcoholic beverages infused with delta-9 THC derived from hemp, distinguishing them from traditional marijuana products. The 2018 Farm Bill legalized hemp and its derivatives, provided they contain no more than 0.3% THC on a dry weight basis. This legal gray area has led to a surge in products that can deliver psychoactive effects while being marketed alongside or as alternatives to alcohol.

    State-by-State Overview

    The rise of hemp and low-dose THC beverages in the market has prompted state alcohol, health, agriculture, and cannabis agencies to review their regulatory frameworks regarding the sale and distribution of these products. Each state approaches the issue differently, which has resulted in a patchwork of regulations across the country.

    • California: The California Department of Alcoholic Beverage Control (ABC) has taken a strict stance on hemp beverages containing THC. On October 3, 2024, the ABC issued an industry advisory stating that alcohol licensed businesses may not carry, market, offer for sale, or sell any industrial hemp products intended for human consumption (including food, beverages, and dietary supplements) that contain a detectable amount of total THC or other intoxicating cannabinoids. Any businesses that do not comply will subject the licensee to disciplinary action. To date, the ABC has already begun enforcement efforts. Recently, ABC agents have been reported visiting licensed locations across the state and seizing hundreds of products from several licensees, removing them from shelves and preventing them from being sold.
    • Massachusetts: On May 30, 2024, the Massachusetts Alcoholic Beverages Control Commission (ABCC) issued an advisory in connection with the joint notice issued by the Massachusetts Department of Public Health (MDPH) and the Massachusetts Department of Agricultural Resources (MDAR) regarding the sale of beverages and food with hemp-derived cannabinoid extracts (CBD) or THC. The ABCC made clear that it is unlawful to manufacture and/or sell food or beverages containing CBD and/or THC. This applies to alcoholic and nonalcoholic beverages. Under the advisory, the ABCC directed that products need to be removed immediately, and anyone found in violation faces potential revocation or suspension of its license. The joint notice and advisory each make clear that they only apply to hemp-derived CBD and THC products and are separate from marijuana products regulated by the Massachusetts Cannabis Control Commission.
    • Minnesota: In contrast to California and Massachusetts, Minnesota explicitly allows the sale of hemp and low-dose THC beverages and provides a clear legal framework for businesses and consumers alike. Beverages can be sold in stores that register with the state prior to sale.
    • Missouri: In August 2024, an executive order was entered banning intoxicating hemp products in the state. The order threatened penalties for any establishment with a Missouri liquor license or that sells food products if they sold hemp-derived THC beverages. The ban also extended to companies producing these beverages in the state. The hemp industry quickly challenged the order by arguing that it was an overreach, and as a result, the regulators went back and limited the scope of the ban. Instead of embargoing products because they contained hemp-THC, regulators have focused on identifying “misbranded” products.
    • New Jersey: Recently, Senate Bill No. 3235 was signed temporarily banning the unlicensed sale of hemp products in New Jersey. The bill bans the sale of any hemp product containing more than 0.3% THC, including delta-9 THC. The bill also mandates that the products are regulated by the New Jersey Cannabis Regulatory Commission (NJCRC) and that manufacturers and retailers of these products must obtain a license from the NJCRC. Initially, the bill required that all intoxicating hemp products be pulled from store shelves until the NJCRC established new regulations. However, a federal judge recently issued a temporary reprieve, allowing these products to remain on shelves while the court reviews the case.
    • Texas: The Texas Senate Committee on State Affairs has been evaluating state laws and regulations surrounding THC-infused beverages. Currently, it is legal to sell hemp-infused beverages in Texas with the proper licensing. Bars and other establishments with the proper licensing can also sell these drinks, either as packaged products or mixed with alcohol. However, the Texas Alcoholic Beverage Commission (TABC) has noted that there are no prepackaged, alcoholic THC-infused products on the market. Currently, the Senate Committee is considering potential legislation to address any ambiguities and ensure consumer safety related to the sale of hemp and low-dose THC beverages in the state.

    Conclusion

    State alcohol beverage agencies are playing a crucial role in regulating the expansion of hemp and low-dose THC beverages. While the popularity of these products continues to grow, the bans and regulations imposed by state agencies reflect a growing concern about the safety and legality of these products. For producers trying to develop a product line, complying with each state’s packaging, labeling, and advertising requirements will be challenging. Accordingly, it is essential for businesses to stay informed about the regulations in their specific states. We are confident that, as more states introduce legislation and agencies clarify their positions, navigating the complex world of hemp and low-dose THC beverages will become more straightforward for the industry and members alike.

    Authors

    Alva C. Mather

    Partner

    Washington, DC

    Christine Dower

    Counsel

    Washington, DC

    More insights
    Endnotes

  • Semiconductor Industry Receives Long-Awaited Tax Credit Guidance From Treasury

    Semiconductor Industry Receives Long-Awaited Tax Credit Guidance From Treasury

    ARTICLE / CLIENT ALERT

    Semiconductor Industry Receives Long-Awaited Tax Credit Guidance From Treasury

    October 25, 2024

    Read time: 8 min

    Key takeaways
    Overview

    On October 22, 2024, the US Department of the Treasury (Treasury) and the Internal Revenue Service (IRS) issued long-awaited regulations implementing the advanced manufacturing investment credit under Sections 48D[1] and 50 (collectively, the Final Section 48D Regulations).[2] The Final Section 48D Regulations retain the general structure of proposed regulations that were issued in March 2023 (March 2023 Proposed Regulations) with certain noteworthy amendments.[3]

    In depth

    Overview

    US Congress enacted the Creating Helpful Incentives to Produce Semiconductors and Science Act of 2022 (CHIPS Act) on August 9, 2022.[4] The CHIPS Act provides a framework for transformative investments to restore and advance US leadership in the research, development, and manufacturing of semiconductors. Congress added Section 48D to the Code as part of the CHIPS Act. Under Section 48D, a taxpayer may be able to claim an amount equal to 25% of its qualified investment for a tax year with respect to an advanced manufacturing facility.[5]

    The Final Section 48D Regulations finalize the March 2023 Proposed Regulations. Together with separately issued regulations addressing direct pay elections for Section 48D credits (e.g., Treas, Reg. § 1.48D-6), these regulations establish the Section 48D guidance base for taxpayers.

    Below, we briefly address changes made to the March 2023 Proposed Regulations by the Final Section 48D Regulations with respect to the definition of “semiconductor manufacturing,” the continuity requirement-related rules, and the parameters of a “significant transaction” as relevant to the applicable transaction rules.

    Changes to Definition of “Semiconductor Manufacturing” Broadens Which Taxpayers Can Avail Themselves of Section 48D Credits

    A taxpayer can only claim Section 48D credits with respect to qualified investment attributable to an advanced manufacturing facility. For this purpose, the term “advanced manufacturing facility” means a facility for which the primary purpose is manufacturing semiconductors or manufacturing semiconductor manufacturing equipment.[6]

    The March 2023 Proposed Regulations defined the term “semiconductor manufacturing” by reference to “semiconductor fabrication” or “semiconductor packaging.”[7] The definitions of the foregoing terms in the March 2023 Proposed Regulations failed to capture the full spectrum of semiconductor activities that a semiconductor manufacturer undertakes. More specifically, semiconductor manufacturing can involve front-end manufacturing, where wafers are fabricated and probed, but also back-end manufacturing, where chips are ultimately assembled, tested, and packaged. The March 2023 Proposed Regulations did not reference “assembly” and “test” activities as in-scope “semiconductor manufacturing” activities.

    In a welcome response to comments, the Final Section 48D Regulations explicitly provide that assembly and test activities qualify as in-scope “semiconductor manufacturing” activities.[8] The Final Section 48D Regulations also clarify that “wafer production” activities (e.g., activities undertaken by manufacturers of solar wafers) are now in-scope “semiconductor manufacturing” activities.[9]

    Together, the above changes serve to broaden the base of taxpayers who can avail themselves of Section 48D credits.

    Taxpayers Now Have More Certainty With Respect to the Beginning of Construction, Continuity Requirements

    A taxpayer must begin construction of credit-eligible property prior to the date that Section 48D sunsets, which is December 31, 2026. A taxpayer may establish that construction of an item of property begins under either a physical work test or a 5% safe harbor.[10] For this purpose, multiple items of qualified property or advanced manufacturing facilities that are operated as part of a “single advanced manufacturing facility project” (Single Project) are treated as a single item of property.[11] Regardless of whether a taxpayer relies on the physical work test or 5% safe harbor to establish the beginning of construction, it must also satisfy a continuity requirement.[12] A taxpayer can satisfy the continuity requirement either by maintaining “continuous construction” or “continuous efforts.” Satisfaction of the continuity requirement is determined based on the relevant facts and circumstances.

    The Final Section 48D Regulations make certain favorable changes to the beginning of construction and continuity requirement-related rules in the March 2023 Proposed Regulations.

    First, the Final Section 48D Regulations incorporate a list of on- and off-site work activities for purposes of the physical work test, which should give taxpayers greater certainty with respect to which activities help satisfy the test as compared to the March 2023 Proposed Regulations (which identified no such examples).[13]

    Second, for purposes of the continuous efforts test, the Treasury and the IRS clarified that a taxpayer has met the factor of paying or incurring additional amounts included in the total cost of the property for a tax year in which it pays or incurs 5% or more of the total cost of the property each calendar year after the calendar year during which construction of the property began.[14] The “paying or incurring additional amounts” factor is one of four nonexclusive factors that a taxpayer can use to establish continuous efforts but arguably can now be viewed as a “super factor” for taxpayers that surpass the 5% spend threshold.

    Third, unlike the March 2023 Proposed Regulations, which provided a list of factors for Single Project treatment but no indication as to how those factors should be weighted, the Final Section 48D Regulations affirmatively provide that a taxpayer can satisfy the Single Project definition with respect to multiple properties if, at any point during construction of the multiple properties or facilities, they are owned by a single taxpayer, and any two or more of the seven factors listed in Treas. Reg. § 1.48D-5(a)(3)(i) are met (e.g., the properties or facilities are constructed on contiguous pieces of land). For this purpose, related taxpayers (e.g., trades or businesses under common control within the meaning of Treas. Reg. § 1.52-1(b)) are treated as one taxpayer in determining whether multiple facilities or properties are treated as a Single Project.[15]

    The revised Single Project test should provide much greater certainty for taxpayers that a particular project constitutes a Single Project. This is particularly important for taxpayers constructing long-lived projects given the Section 48D credit sunset date. More specifically, if a taxpayer continues to construct a part of a Single Project, the construction of which began before the Section 48D credit sunsets, it can now more easily tie back property that it places in service in a post-2026 year attributable to the Single Project itself and, in turn, rely on the Single Project’s beginning of construction date to claim credits for the post-2026 placed in service property (assuming satisfaction of other applicable rules).

    Together, the above changes provide additional certainty to taxpayers, which is especially important considering the IRS will not issue private letter rulings for the beginning of construction requirement and is similarly not expected to issue private letter rulings with respect to the continuity requirement.

    The Revised Scope of a “Significant Transaction” Providers Greater Certainty for What Triggers the Applicable Transactions Rules

    If an applicable taxpayer engages in an applicable transaction before the close of the applicable period in the tax year that the applicable transaction occurs, then the applicable taxpayer must recapture Section 48D credits that it claimed in prior tax years.[16] Further, any applicable taxpayer that engages in an applicable transaction during a certain tax year cannot meet the eligible taxpayer definition and, in turn, cannot claim Section 48D credits for that tax year.[17] The term “applicable transaction” means, with respect to any applicable taxpayer, any significant transaction involving the material expansion of semiconductor manufacturing capacity of such applicable taxpayer in any foreign country of concern.[18] In the March 2023 Proposed Regulations, the Treasury provided a laundry list of events that constituted a “significant transaction,” which included, in part, any investment – whether proposed, pending, or completed – that is valued at $100,000 or more, including (i) a merger, acquisition, or takeover and (ii) any other investment, including any capital expenditures or the formation of a subsidiary.[19] Importantly, the definition of a “significant transaction” differed in certain respects from the definition of the same term for purposes of the US Department of Commerce (Commerce) rules (e.g., 15 CFR part 231).

    In response to comments, the Final Section 48D Regulations materially amend the scope of a “significant transaction.” In particular, the significant transaction rules for a CHIPS Act funds recipient now leverage the taxpayer’s agreement with Commerce: if a taxpayer enters into a “required agreement” with Commerce (e.g., an agreement for CHIPS Act funds), then the term “significant transaction” has the same meaning as provided in the required agreement.[20] This uniformity provides taxpayers negotiating for CHIPS Act funds an opportunity to weigh in on the scope of a “significant transaction” as applicable to their facts. Taxpayers who will not receive CHIPS Act funds still benefit from the updated rules, which streamline the definition of a “significant transaction” and, importantly, largely allow taxpayers to sidestep applicable transaction treatment for ordinary course of business transactions (e.g., funding payroll).

    Conclusion

    Overall, the Final Section 48D Regulations provide welcome guidance to taxpayers and reflect an open-eared Treasury that clearly listened to taxpayer feedback to make certain changes to the March 2023 Proposed Regulations. The combination of the above changes, as well as others not mentioned herein, provides greater certainty to taxpayers who intend to make the types of transformative investments in the research, development, and manufacturing of semiconductors that Congress desired when it promulgated Section 48D.

    Authors

    Mike Tenenboym

    Partner

    Chicago

    More insights

  • New Pharmaceutical Industry Standards Apply to the Promotion of Medicines in the United Kingdom: ABPI Code 2024 and the PMCPA Constitution and Procedure

    New Pharmaceutical Industry Standards Apply to the Promotion of Medicines in the United Kingdom: ABPI Code 2024 and the PMCPA Constitution and Procedure

    ARTICLE / CLIENT ALERT

    New Pharmaceutical Industry Standards Apply to the Promotion of Medicines in the United Kingdom: ABPI Code 2024 and the PMCPA Constitution and Procedure

    October 25, 2024

    Read time: 6 min

    Key takeaways
    Overview

    Pharmaceutical companies promoting prescription-only medicines to health professionals and other relevant decision makers in the UK must now adhere to revised industry standards that came into operation from 1 October 2024 under the Association of the British Pharmaceutical Industry (ABPI) 2024 Code of Conduct (Code). Whilst compliance with the Code is not a legal requirement, it is a condition of membership of the ABPI, and most non-member companies agree to comply with it as evidence of good practice.

    The new Code follows a period of consultation which concluded earlier this year and seeks to align UK requirements with standards set in the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) Codes.

    Since the new Code was published, the Prescription Medicines Code of Practice Authority (PMCPA), the self-regulatory body established to independently operate the Code, has released a new learning portal platform with educational materials aimed at supporting pharmaceutical companies through the changes to the Code (access the PMCPA learning portal).

    In depth

    Changes to Note

    Key changes to note if you are a pharmaceutical company promoting medicines in the UK:

    • the PMCPA has a revised ‘Constitution and Procedure’ with a new process for the assessment and management of complaints made under the Code;
    • prescribing information may now be provided in certain promotional materials via a QR code; and
    • previous recommended guidance has now becoming mandatory.

    Relevant companies have until 31 December 2024 to implement the requirements of the new Code before they become mandatory. However, the revised PMCPA Constitution and Procedure framework is already in effect.

    Constitution and Procedure

    The Code has always included processes for dealing with complaints as part of the PMCPA’s role as both administrator and adjudicator. The new Code includes significantly more detail on the complaints process, including with respect to appointments to the Appeal Board.

    A key new inclusion is an ‘abridged’ complaints process intended as a more proportionate route to complaint resolution.

    The abridged process allows the PMCPA to “triage” complaints and if (i) the breach falls within the PMCPA’s approved list (published online); (ii) the central facts are not disputed; and (iii) it is likely to be determined there has been clear breach, then respondents have 15 days to respond on whether the breach is accepted, to provide assurances there are no systemic compliance issues and to provide the PMCPA with appropriate undertakings as to remedies. The PMCPA may escalate to a full complaint investigation where responses are inadequate or where patient safety concerns are identified.

    Examples of breaches that fall within the approved list are broad and include failures to disclose transfers of value on time and breaches of administrative Code requirements (e.g. delay in notifying PMCPA of updated signatories, incorrect certificate wording on materials).

    This new process may mean technical breaches of the Code may be resolved more efficiently reducing the burden on respondents to provide detailed responses (as required under the longer complaints process) and freeing up time for the PMCPA to focus on investigating serious breaches.

    The PMCPA also encourages complainants to seek to resolve disputes internally in the first instance where possible, e.g., through whistleblowing procedures. Hence, pharmaceutical companies may want to review their internal processes for managing complaints and whistleblowing procedures.

    For complaints that warrant a full investigation, the PMCPA has introduced the concept of ‘case management directions’ setting out greater administrative powers, for example on redactions to materials. This indicates a more formal approach to the governance of complaints and is aligned with court procedures.

    Prescribing Information

    Under the new Code, prescribing information (being the essential information that must be included in all promotional material such as the list of active ingredients and authorised indications or the medicine’s Summary of Product Characteristics (SPC)) may now be provided via a QR code where the material is printed or for certain digital promotional material. The QR code cannot be used where the recipient needs to use two devices (e.g., a website and a separate phone) to access the information but could be used on a fixed digital display at a promotional booth.

    The use of QR codes is an efficient paper-free way of giving prescribing information and ensuring material remains up to date. Where companies are promoting new indications of a medicine that are not yet included in the medicine’s SPC, the prescribing information must still be accurate and the PMCPA have confirmed no grace period applies.

    Different rules apply to short form and abbreviated materials.

    New Mandatory Requirements

    Some parts of the Code are now mandatory rather than guidance:

    • Gateway Links on Disclosure UK: Companies were previously encouraged to disclose through the gateway under the principles of the 2021 Code; this has now become a mandatory process. Companies must also disclose relevant transfers of value using the updated mandatory template. 2024 disclosures are due by 14:00 GMT Friday, 28 March 2025.
    • Support for Health Professionals and Decision Makers: It is now mandatory, rather than just recommended good practice, to have written terms when companies provide support to individual health professionals and relevant decision makers.

    Looking to the Future – Sunshine Ahead?

    In addition to self-regulatory frameworks, the pharmaceutical and health technology industry continues to wait for the outcome of the UK government’s 2023 public consultation on whether statutory requirements for the disclosure of transfers of value to hospitals, research institutions and healthcare professionals in line with similar systems in place internationally, such as the Sunshine Act in the United States and in the Netherlands and France.

    If proposals under the consultation are enacted, manufacturers and commercial suppliers of healthcare products may also be subject to statutory obligations to disclose transfers of value provided to healthcare professionals and organisations from powers granted under the Health and Care Act 2022.

    Authors
    More insights

  • Illinois Passes New Physical Therapy Law HB 5087

    Illinois Passes New Physical Therapy Law HB 5087

    ARTICLE / CLIENT ALERT

    Illinois Passes New Physical Therapy Law HB 5087

    October 24, 2024

    Read time: 4 min

    Key takeaways
    Overview

    Key update

    Illinois enacted HB 5087, which significantly limits physical therapists’ ability to provide telehealth services to patients in the state. As enacted, these new provisions become effective on January 1, 2025. In this article, we discuss the new legislation and its impact on telehealth providers and patients in further detail.

    Legislative update

    Under the enacted legislation, effective on January 1, 2025, the Illinois Physical Therapy Act is amended by adding a new section, 225 ILCS 90/1.3, regarding telehealth services.

    This new section requires that physical therapists (or physical therapist assistants working under the general supervision of a physical therapist) that provide physical therapy through telehealth services pursuant to the terms and use defined in the Telehealth Act and the Illinois Insurance Code are additionally subject to the following conditions:

    • Initial physical therapy evaluations without a referral or established diagnosis may only be performed by a licensed physical therapist and cannot be performed via telehealth unless necessary to address a documented hardship, including but not limited to geographical, physical, or weather-related conditions.
    • The use of telehealth as a primary means of delivering physical therapy must be an exception, and documentation must support the clinical justification.
    • A patient receiving physical therapy must be able to request and receive in-person care at any point during their treatment.
    • A physical therapist providing telehealth must have the capacity to provide in-person care within the state of Illinois.

    Why it matters

    • The above conditions significantly increase the barriers for both telehealth providers and patients seeking remote telehealth physical therapy services.
    • The legislation introduces new requirements, such as prohibiting telehealth unless there is a documented hardship such as physical, geography or weather-related hardships, but does not further elaborate on how such hardships should be evaluated or documented (if at all). Requiring this heightened standard poses significant barriers to the delivery physical therapy via telehealth to Illinois patients.
    • The additional requirement for providers to have the capacity to provide in-person care within the state of Illinois significantly limits many remote physical therapy providers who are otherwise licensed and duly authorized to practice within the state of Illinois, by requiring them to offer a physical space in which to offer care or to arrange for such accommodations – thus decreasing patient access to otherwise authorized physical therapy providers that can provide these beneficial services to patients in need.
    • While the enacted legislation does not address payors, carriers should closely evaluate and update their current coverage and reimbursement policies related to physical therapy provided via telehealth to align with the new standards in Illinois. Likewise, providers should assess the impact of these restrictions on their current practice.

    —
    Telehealth is an important development in care delivery, but the regulatory patchwork is complicated. The McDermott digital health team works alongside the industry’s leading providers, payors, and technology innovators to help them enter new markets, break down barriers to delivering accessible care, and mitigate enforcement risk through proactive compliance. Are you working to make healthcare more accessible through telehealth? Let us help you transform telehealth.

    In depth

    TEMP

    Authors

    Patrick Zanayed

    Partner

    Chicago

    Jayda Greco

    Partner

    Chicago

    Lisa Mazur

    Partner

    Chicago

    Marshall E. Jackson , Jr.

    Partner

    Washington, DC

    Amanda Enyeart

    Partner

    Chicago

    Stacey L. Callaghan

    Partner

    Chicago

    More insights

  • Election 2024: Privacy in the US

    Election 2024: Privacy in the US

    ARTICLE

    Election 2024: Privacy in the US

    October 23, 2024

    Read time: 3 min

    Key takeaways
    Overview

    Read how the outcome of the 2024 US election could affect clients in the privacy space. Partners Elliot Golding, Stephen Reynolds, David Saunders, and Alexander Southwell contributed their thoughts.

    In depth

    What might 2025 bring at the state level for consumer data privacy laws?

    We anticipate that more state consumer privacy laws will be enacted. The question is whether those new laws will mirror existing laws or continue the recent trend of breaking the mold and introducing new consumer rights or compliance obligations.

    We are also watching the explosion of sector-specific privacy laws related to, for example, health, biometrics, and children. Health data likely will remain a focus in 2025, but everyone seems to be talking about children’s privacy.

    How would a Harris-Walz administration affect your clients?

    As we’ve seen during the Biden administration, Democratic presidents are not shy about using Executive Orders to attempt to impose privacy and data security requirements on government contractors. However, the president will generally be less influential than Congress with respect to privacy legislation.

    On the enforcement side, the Federal Trade Commission (FTC) under Harris-Walz would likely continue to use its authority to aggressively police privacy at the federal level.

    How would a Trump-Vance administration affect your clients?

    With respect to privacy legislation, as noted above, the president will be less influential than Congress. However, under a Trump-Vance administration, it is likely that the FTC would retreat from its current, aggressive enforcement posture, which is something that we witnessed during the first Trump administration.

    Which provisions in existing state data privacy models do you anticipate will spread to new states in 2025?

    Potentially Maryland’s prohibition on selling sensitive personal information or Minnesota’s right of consumers to request a rerun of decisions subject to automated decision making if the inputs were incorrect.

    What do you think the impact of state attorneys general will be in a new administration?

    In a Trump administration, we would expect more activity and enforcement from Democratic state attorneys general (as we saw during the last Trump administration) but less cooperation with federal regulators (as we’ve increasingly seen during the Biden administration). In a Harris administration, the activity of Republican state attorneys general would likely increase, and close cooperation with federal regulators, particularly the FTC, would likely continue.

    What should clients be most focused on from a regulatory, enforcement, and/or litigation perspective with a new administration?

    Enforcement is the key, rather than legislation. A new administration will always impact how aggressive federal agencies will be.

    Authors

    Elliot R. Golding

    Partner

    Washington, DC

    David P. Saunders

    Partner

    Chicago

    More insights